Adult-onset Still’s Disease – Epidemiology Forecast to 2030

Adult-onset Still’s Disease – Epidemiology Forecast to 2030

  • December 2020 •
  • 65 pages •
  • Report ID: 5993619 •
  • Format: PDF
‘Adult-onset Still’s Disease – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical, and forecasted Adult-onset Still’s Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030

Adult-onset Still’s Disease: Understanding

The Adult-onset Still’s Disease (AOSD) epidemiology report gives a thorough understanding of AOSD by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for AOSD in the US and Europe. Moreover, the report covers the AOSD scenario’s detailed information in seven major countries (US, EU5, and Japan).

Epidemiology Perspective

This section encompassing adult-onset Still’s disease epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries. The AOSD epidemiology data are studied through all possible divisions to understand the disease scenario in 7MM better. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Detailed Epidemiology Segmentation

The AOSD epidemiology covered in the report provides historical and forecasted AOSD epidemiology scenarios in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

Report Highlights

• 11-year Forecast of Adult-onset Still’s Disease Epidemiology
• 7MM Coverage
• Total Prevalent cases of Adult-onset Still’s Disease
• Diagnosed Cases of Adult-onset Still’s Disease
• Severity-specific Cases of Adult-onset Still’s Disease
• Gender-specific Cases of Adult-onset Still’s Disease
KOL Views

We interview KOLs and include SME’s opinion through primary research to fill the data gaps and validate our secondary research. The view helps understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM concerning the patient population pertaining to adult-onset Still’s disease?
• What are the key findings pertaining to the adult-onset Still’s disease epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of adult-onset Still’s disease across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow by in the 7MM during the forecast period (2017–2030)?
• What are the disease risks, burdens, and unmet needs of adult-onset Still’s disease?
• What are the currently available treatments of adult-onset Still’s disease?

Reasons to buy
The Adult-onset Still’s Disease Epidemiology report will allow the user to:
• Develop business strategies by understanding the trends shaping and driving the global adult-onset Still’s disease market.
• Quantify patient populations in the global adult-onset Still’s disease to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for adult-onset Still’s disease therapeutics in each of the markets covered.
• Understand the magnitude of the adult-onset Still’s disease population by its epidemiology.
• The adult-onset Still’s disease Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population